Related Experiment Videos
Buprenorphine detoxification from opioid dependence: a pilot study
1Yale University School of Medicine, Psychiatry Department, New Haven, Ct. 06519.
Life Sciences
|January 1, 1988
Summary
Buprenorphine treatment for opioid dependence showed excellent retention and infrequent illicit opioid use. While dosage didn't impact retention, the 4 mg group experienced fewer withdrawal symptoms.
Area of Science:
- Addiction Medicine
- Pharmacology
- Clinical Research
Background:
- Opioid dependence is a significant public health issue.
- Effective pharmacological treatments are crucial for managing opioid use disorder.
- Buprenorphine is an established medication for opioid addiction treatment.
Purpose of the Study:
- To evaluate the efficacy of buprenorphine in treating opioid-dependent patients.
- To assess treatment retention and illicit opioid use.
- To examine the impact of different buprenorphine dosages on withdrawal symptoms.
Main Methods:
- Sixteen opioid-dependent patients were enrolled.
- Treatment involved buprenorphine at 2 mg, 4 mg, or 8 mg for one month.
- Data collected included treatment retention, urine toxicology for illicit opioids, and withdrawal symptom assessment.
Main Results:
- Excellent treatment retention was observed, with only one patient discontinuing due to withdrawal.
- Illicit opioid use was infrequent, detected in only 22% of urine samples.
- While buprenorphine dose did not correlate with retention or illicit use, the 4 mg group showed a significant reduction in withdrawal symptoms compared to other groups.
Conclusions:
- Buprenorphine demonstrates high treatment retention and low illicit opioid use in opioid-dependent patients.
- The 4 mg buprenorphine dosage may be particularly effective in mitigating withdrawal symptoms.
- Further research into optimal dosing strategies for buprenorphine is warranted.